Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Standard Chemotherapy for Lymph Node Positive Bladder Cancer
NCT05137262Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2021
- Primary completion
- Aug 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in urothelial carcinoma (UC), bladder cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2021; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
urothelial carcinoma (UC)bladder cancer
Beyond the preview
Go deeper on NCT05137262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137262.